Trending...
- New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
- City of Spokane Prepared For Forecasted Winds
- City of Tacoma Elevates 28-Year South African Sister City Relationship to District-Wide Partnership
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global recurrent glioblastoma multiforme treatment market is estimated to be valued at US$ 369.6 million in 2020 and is projected to exhibit a CAGR of 6.14% during the forecast period (2020-2027).
Key Trends and Analysis:
The global recurrent glioblastoma multiforme treatment market is expected to witness noteworthy growth, owing to advancements in treatment and novel drug approvals. For instance, in January 2020, Pfizer launched a bevacizumab biosimilar drug, 'Zirabev', in the U.S. for the treatment of recurrent glioblastoma multiforme. Zirabev acts as a substitute for Avastin and is priced at a WAC (Wholesale Acquisition Cost) of US$ 61.34 per 10 mg. The U.S. FDA approved this biosimilar in June 2019 for the treatment of recurrent glioblastoma multiforme, metastatic or recurrent NSCLC, recurrent/persistent or metastatic cervical cancer, metastatic colorectal cancer, and metastatic renal cell carcinoma.
For instance, in November 2019, the U.S. FDA accepted Samsung's BLA application for SB8 bevacizumab, a biosimilar of Avastin. If this will gets approval, thisen, the biosimilar will be commercialized in the U.S. market by Merck & Co., Inc., which has also been Samsung's partner on its biosimilar of infliximab – RenflexisKey industry players are implementing research collaborations and joint ventures to discover & develop novel drugs, which is significantly driving growth of the market. For instance, in October 2019, UCLA and Advaxix jointly entered into an agreement for research on GBM immunotherapy products. The companies aimed to conduct preclinical studies evaluating the Lm technology of UCLA in mouse tumor models of glioblastoma multiforme.
More on Washingtoner
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/682
Key Market Takeaways:
The global recurrent glioblastoma multiforme treatment market is expected to exhibit a CAGR of 6.1% during the forecast period (2020-2027), owing to the collaborations by key players. For instance, in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences, in order to conduct VAL-083's phase III trials for the treatment of recurrent glioblastoma multiforme.
North America recurrent glioblastoma multiforme treatment market is expected to be the most lucrative region during the forecast period, owing to increasing investments in R&D activities and FDA approvals for clinical trials in this region. For instance, in October 2019, Denovo Biopharma was granted the FDA approval for its phase IIb clinical trial assessing an analytical permutation therapy for the treatment of newly diagnosed GBM patients.
Competitive Landscape:
Key players operating in the global recurrent glioblastoma multiforme treatment market include GlaxoSmithKline plc., GW Pharmaceuticals Plc, AstraZeneca, ImmunoCellular Therapeutics, Ltd., F. Hoffman-La Roche, Ltd., Genzyme Corporation, Pfizer, Inc., ERC Belgium SA, Merck & Co., Inc., GenSpera, Inc., Vascular Biogeneics, EnGeneIC Ltd., AngioChem, Inc., Boehringer Ingelheim GmbH, Cortice Biosciences, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Boston Biomedical, Inc., Eisai, Cantex Pharmaceuticals, Inc., Coherus BioSciences, Inc., Celldex Therapeutics, Inc., and Cavion LLC
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/682
More on Washingtoner
Market Segmentation:
Related Market Intelligence Reports:
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Key Trends and Analysis:
The global recurrent glioblastoma multiforme treatment market is expected to witness noteworthy growth, owing to advancements in treatment and novel drug approvals. For instance, in January 2020, Pfizer launched a bevacizumab biosimilar drug, 'Zirabev', in the U.S. for the treatment of recurrent glioblastoma multiforme. Zirabev acts as a substitute for Avastin and is priced at a WAC (Wholesale Acquisition Cost) of US$ 61.34 per 10 mg. The U.S. FDA approved this biosimilar in June 2019 for the treatment of recurrent glioblastoma multiforme, metastatic or recurrent NSCLC, recurrent/persistent or metastatic cervical cancer, metastatic colorectal cancer, and metastatic renal cell carcinoma.
For instance, in November 2019, the U.S. FDA accepted Samsung's BLA application for SB8 bevacizumab, a biosimilar of Avastin. If this will gets approval, thisen, the biosimilar will be commercialized in the U.S. market by Merck & Co., Inc., which has also been Samsung's partner on its biosimilar of infliximab – RenflexisKey industry players are implementing research collaborations and joint ventures to discover & develop novel drugs, which is significantly driving growth of the market. For instance, in October 2019, UCLA and Advaxix jointly entered into an agreement for research on GBM immunotherapy products. The companies aimed to conduct preclinical studies evaluating the Lm technology of UCLA in mouse tumor models of glioblastoma multiforme.
More on Washingtoner
- R2 Copilot Addresses Critical Privacy Issues as Enterprise AI Spending and Security Incidents Rise
- Innovative Environmental Technologies Unveils New Website Featuring Free AI Tools for the Environmental Industry
- CCHR Warns: Psychiatric Diagnoses Without Biological Proof Now Used to Justify Euthanasia
- Impact Filtration Appoints Alejandro Sturniolo as Head of Sustainability to Engineer High-Performance, Water-Positive Infrastructure
- Spokane: 2025 Longitudinal Systems Analysis Shows Decreased Need for Homeless Services, Increase in Successful Exits to Stability
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/682
Key Market Takeaways:
The global recurrent glioblastoma multiforme treatment market is expected to exhibit a CAGR of 6.1% during the forecast period (2020-2027), owing to the collaborations by key players. For instance, in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences, in order to conduct VAL-083's phase III trials for the treatment of recurrent glioblastoma multiforme.
North America recurrent glioblastoma multiforme treatment market is expected to be the most lucrative region during the forecast period, owing to increasing investments in R&D activities and FDA approvals for clinical trials in this region. For instance, in October 2019, Denovo Biopharma was granted the FDA approval for its phase IIb clinical trial assessing an analytical permutation therapy for the treatment of newly diagnosed GBM patients.
Competitive Landscape:
Key players operating in the global recurrent glioblastoma multiforme treatment market include GlaxoSmithKline plc., GW Pharmaceuticals Plc, AstraZeneca, ImmunoCellular Therapeutics, Ltd., F. Hoffman-La Roche, Ltd., Genzyme Corporation, Pfizer, Inc., ERC Belgium SA, Merck & Co., Inc., GenSpera, Inc., Vascular Biogeneics, EnGeneIC Ltd., AngioChem, Inc., Boehringer Ingelheim GmbH, Cortice Biosciences, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Boston Biomedical, Inc., Eisai, Cantex Pharmaceuticals, Inc., Coherus BioSciences, Inc., Celldex Therapeutics, Inc., and Cavion LLC
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/682
More on Washingtoner
- 106 Years Strong: The Liberty Group Celebrates a Century-Plus of Service and Unveils a Unified Family of Companies
- Airport Transportation Reaches All Five Continents Through Global Transportation Partner Network
- Acquisition of Israeli Defense Manufacturing Platform to Accelerate AI-Driven Autonomous Systems: VisionWave Holdings, Inc.: (N A S D A Q: VWAV)
- HRC Fertility to Celebrate Grand Opening of New Beverly Hills Location During National Infertility Awareness Week
- AktieGo Publishes Editorial Feature Examining Decentralized Power Infrastructure and Hydrogen Energy Deployment
Market Segmentation:
- By Treatment:
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
- By Type:
- Grade II or Grade III
- Grade IV
- Others
- By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Region:
- North Africa
- Central Africa
- South Africa
- By Region:
- North America
Related Market Intelligence Reports:
Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Read more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
0 Comments
Latest on Washingtoner
- Pastor Saeed Abedini Releases THE TRUTH – Volume 1, A Deeply Personal Story of Faith, Struggle, and Redemption
- New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
- City of Spokane Prepared For Forecasted Winds
- Scotch Whisky Market Dislocation Creates Compelling Entry Opportunity for Long-Term Investors
- Peccioli Becomes New Orleans: In July 2026, the magic of jazz comes to Tuscany
- Spokane: Flags to be Lowered in Remembrance of Reverend Jesse Jackson
- $6 Million Funding Secured as Retail Expansion, Operational Streamlining, and Asset-Light Strategy Position the Company for Accelerated Growth $SOWG
- Why Your Dental Practice Ranks on Google But Still Is Not Getting New Patients
- The "Unsexy" Business Quietly Creating 130+ New Entrepreneurs Across America — From Alaska to Puerto Rico
- Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
- City of Tacoma Elevates 28-Year South African Sister City Relationship to District-Wide Partnership
- RecallSentry™ App Launch — Your Home Safety Hub — Free on iOS & Android
- Award-Winning Director Crystal J. Huang's Under-$50K Film "The Ritual House" Wins Best Horror Feature at Golden State Film Festival
- Grads aren't getting hired — here's what we're doing about it
- Spokane: Man Arrested for Fleeing Police and Colliding With a Patrol Vehicle
- Tacoma: Asphalt Repairs on Ruston Way to Cause Single-Lane Traffic and Delays on Saturday, March 21
- K2 Integrity Enhances Technology Capabilities Through Acquisition of Leviathan Security Group
- #WeAreGreekWarriors Comes to Detroit in Celebration of Women's History Month
- Energywise Solutions and Pickleball Pros Partner to Bring More Energy and Visibility to Pickleball Clubs
- Buildout Launches CRM, Completing the Industry's First AI-Powered End-to-End Deal Engine for CRE